Gain Therapeutics

Neuron
#Gain Therapeutics #Neurodegenerative disorders #Neuroscience #Parkinson's #Phase I trial

Early data suggest GT-02287 slows Parkinson’s disease

Gain Therapeutics has shared early safety and tolerability findings, the primary endpoint, and observations from key exploratory endpoints from the Phase Ib clinical study of GT-02287 in people with Parkinson’s disease (PD) with or without a GBA1 mutation.  The findings were presented in a poster at the… Read More

#News #Trending News

#Events #Gain Therapeutics #Neuroscience 2024 #Parkinson's #Society for Neuroscience

Vodcast: Joanne Taylor, Gain Therapeutics, at Neuroscience 2024

At the Society for Neuroscience’s annual meeting, Neuroscience 2024, which took place in October 2024 in Chicago, DDW’s Megan Thomas met with Joanne Taylor, Senior Vice President of Research at Gain Therapeutics. Read More

#Videos

Neuroscience Parkinson's disease
#Clinical trials #Gain Therapeutics #Neuroscience #Parkinson's

Restored motor function in mouse models of Parkinson’s disease  

Gain Therapeutics has announced preclinical data demonstrating that its clinical-stage GCase regulator GT-02287 provided neuroprotection and restored motor function in Parkinson’s disease models following delayed administration.   The data were accepted as a late-breaker abstract and was presented at the 20th Annual WORLDSymposium.  “We… Read More

#News

Parkinson's disease
#Gain Therapeutics #Genetics / genomics #Neurodegenerative disorders #Neuroscience #Parkinson's #Phase I trial

Allosteric therapy targets common genetic cause of Parkinson’s

Gain Therapeutics has initiated a Phase I clinical trial of GT-02287, the company’s lead drug candidate for the treatment of GBA1 Parkinson’s disease. Preclinical data demonstrated that GT-02287 can restore the function of the lysosomal enzyme glucocerebrosidase (GCase), which becomes misfolded and dysfunctional due to a… Read More

#News